| AMGN |
Report |
Total Revenue (Q2 2026) |
BEAT |
pred ~$9.52B vs. cons $9.43B |
MEDIUM |
| AMGN |
Report |
Non-GAAP EPS (Q2 2026) |
BEAT |
pred ~$5.65 vs. cons $5.58 |
MEDIUM |
| AMGN |
Report |
UPLIZNA (Q2 2026) |
BEAT |
pred ~$320M vs. cons $305M |
MEDIUM |
| AMGN |
Guide |
FY 2026 Revenue (FY 2026) |
BETTER |
guide midpoint ~$38.15B vs. cons $37.82B |
MEDIUM |
| AMGN |
Guide |
FY 2026 Non-GAAP EPS (FY 2026) |
BETTER |
guide midpoint ~$22.70 vs. cons $22.36 |
MEDIUM |
| AMGN |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
MEDIUM |
| AMGN |
Return |
5-day cumulative residual |
-3.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — sell-side trims H2 estimates on modest implied H2 growth; cybersecurity tail risk extends pressure |
MEDIUM |